105 related articles for article (PubMed ID: 16515577)
1. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response.
Klostergaard J; Auzenne E; Ghosh S; Farquhar D; Rivera B; Price RE
Int J Gynecol Cancer; 2006; 16 Suppl 1():111-7. PubMed ID: 16515577
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
4. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
6. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
Burbridge MF; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
Int J Oncol; 1999 Dec; 15(6):1155-62. PubMed ID: 10568822
[TBL] [Abstract][Full Text] [Related]
7. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
Terauchi F; Moritake T; Yamamoto Y; Ogura H
Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
[TBL] [Abstract][Full Text] [Related]
9. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.
De Stefano I; Battaglia A; Zannoni GF; Prisco MG; Fattorossi A; Travaglia D; Baroni S; Renier D; Scambia G; Ferlini C; Gallo D
Cancer Chemother Pharmacol; 2011 Jul; 68(1):107-16. PubMed ID: 20848284
[TBL] [Abstract][Full Text] [Related]
11. [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
Huang SG; Kong BH; Yang RF; Jiang S
Ai Zheng; 2002 Apr; 21(4):401-4. PubMed ID: 12452020
[TBL] [Abstract][Full Text] [Related]
12. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
13. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice.
Dou YN; Zheng J; Foltz WD; Weersink R; Chaudary N; Jaffray DA; Allen C
J Control Release; 2014 Mar; 178():69-78. PubMed ID: 24440663
[TBL] [Abstract][Full Text] [Related]
14. A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer.
Sarkar S; Malekshah OM; Nomani A; Patel N; Hatefi A
Cancer Med; 2018 Aug; 7(8):3630-3641. PubMed ID: 29926538
[TBL] [Abstract][Full Text] [Related]
15. Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study.
Nicoletto MO; Padrini R; Palumbo M; Ziade A; Ragazzi RS; Pratesi G; Artioli G; De Cesare M; Zunino F
Oncol Rep; 2002; 9(6):1351-4. PubMed ID: 12375047
[TBL] [Abstract][Full Text] [Related]
16. Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.
Stuckey A; Fischer A; Miller DH; Hillenmeyer S; Kim KK; Ritz A; Singh RK; Raphael BJ; Brard L; Brodsky AS
BMC Cancer; 2011 Jul; 11():308. PubMed ID: 21781307
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and
Nguyen-Thu H; Hanaoka H; Nakajima T; Yamaguchi A; Nguyen-Cong T; Kartamihardja AAP; Tsushima Y
Breast Cancer; 2018 May; 25(3):334-342. PubMed ID: 29357023
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
20. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Battelli C; Campo M; Buss MK; Awtrey CS; Konstantinopoulos PA
Chemotherapy; 2013; 59(4):251-9. PubMed ID: 24457572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
